Patents Examined by Sreeni Padmanabhan
  • Class of non-stimulant treatment and ADHD and related disorders
    Patent number: 9623023
    Abstract: Described is a method of administering nor-binaltorphimine (nor-BNI) or a nor-BNI analog to an individual having Attention Deficit/Hyperactivity Disorder (ADHD) to thereby reduce the effects of ADHD in the individual.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: April 18, 2017
    Assignees: The Florida State University Research Foundation, Incorporated, The General Hospital Corporation
    Inventors: Pradeep G. Bhide, Jinmin Zhu, Joseph Biederman, Thomas J. Spencer
  • Stabilized granules containing glyceryl trinitrate
    Patent number: 9616023
    Abstract: Solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight % glyceryl trinitrate, at least one carrier material, and at least one substance that reduces the volatility of the GTN, whereby this substance is a non-volatile ester stabilizer.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: April 11, 2017
    Assignee: G. Pohl-Boskamp GmbH & Co. KG
    Inventors: Thomas Zimmeck, Henning Ueck, Julia Gehricke
  • Companion animal compositions including pyruvic acid and salts thereof and methods of use thereof
    Patent number: 9596872
    Abstract: The invention encompasses pet food compositions and methods for the treatment and/or prevention of diseases or disorders in companion animals, for example, for the treatment or obesity, including administering a pet food composition including pyruvic acid or a salt thereof to a companion animal, or lipoic acid or salt thereof and pyruvic acid or a salt thereof to a companion animal. The invention encompasses pet food compositions and methods for managing weight including administering a pet food composition including pyruvic acid or a salt thereof, or lipoic acid or a salt thereof and pyruvic acid or a salt thereof to a companion animal to a companion animal.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: March 21, 2017
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Ryan Michael Yamka, Nolan Zebulon Frantz, Steven C. Zicker
  • Treatment of cognitive disorders associated with abnormal dendritic spines using PKC activators
    Patent number: 9597312
    Abstract: The present disclosure provides methods of treating a cognitive disorder associated with abnormal dendritic spines, such as Fragile X Syndrome, Fragile X Associated Tremor/Ataxia Syndrome, autism, or mental retardation, using PKC activators.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: March 21, 2017
    Assignee: Cognitive Research Enterprises, Inc.
    Inventors: Miao-kun Sun, Daniel L. Alkon
  • Inhibition of renal fibrosis
    Patent number: 9572787
    Abstract: The invention provides compositions and methods for inhibiting renal fibrosis.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: February 21, 2017
    Assignee: Rhode Island Hospital
    Inventor: Shougang Zhuang
  • Cell permeable inhibitors of anaphase promoting complex
    Patent number: 9572788
    Abstract: The disclosure provides compositions and methods for treating cell cycle disorders. Compositions of the disclosure include proTAME, a prodrug analog of TAME and apcin, the combination of which inhibits an activity or function of the anaphase promoting complex (APC) by a synergistic mechanism.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: February 21, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Randall King, Xing Zeng, Katharine L. Sackton
  • Pharmaceutical compositions comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
    Patent number: 9555021
    Abstract: Disclosed herein is a pharmaceutical composition comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol and methods of using the composition to treat chronic pain.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: January 31, 2017
    Assignee: Allergan, Inc.
    Inventor: Daniel W. Gil
  • Antimicrobial compositions and methods for their use
    Patent number: 9555015
    Abstract: Topical and wash compositions comprising a polymeric biguanide or a bis(biguanide) compound, a chelating agent and a buffering agent and methods for using these compositions for the prevention or treatment of skin or ear tissue infections is provided.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: January 31, 2017
    Assignee: Dermcare-Vet Pty Ltd
    Inventor: Kenneth Vincent Mason
  • Pharmaceutical composition for treating a microbial infection
    Patent number: 9549965
    Abstract: The present invention relates to a combination comprising at least one compound selected from the group consisting of an ?-adrenergic antagonist, an anthelmintic agent, an antifungal agent, an antimalarial agent, an antineoplastic agent, an antipsychotic agent, an antioxidant, a vasodilator, a vitamin, or a pharmaceutically acceptable derivative thereof; and an antimicrobial compound.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: January 24, 2017
    Assignee: Helperby Therapeutics Limited
    Inventors: Yanmin Hu, Anthony R M Coates
  • Method of destroying bacterial biofilm using sterile intravenous or intracavernous glycerin
    Patent number: 9549904
    Abstract: Disclosed is a method of preventing or inhibiting biofilm formation by a population of bacteria comprising the administration of a sterile intravenous normal saline solution containing glycerin and amino acids. In some embodiments, the concentration of glycerin in the normal saline solution is approximately 3%. In some embodiments, the concentration of amino acids in the normal saline solution is approximately 3%. In some embodiments, the intravenous solution is administered for 48 hours at 80 cc/hour. In some embodiments, the solution is infused via intracavernous administration into an infected body cavity.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: January 24, 2017
    Inventor: Thomas Bryan
  • Methods and compositions for treating pain
    Patent number: 9545393
    Abstract: Methods and compositions are provided for treating pain in an individual. Aspects of the methods include administering to the individual an agent that promotes ALDH activity. These methods find many uses, for example in treating and preventing nociceptive pain, inflammatory pain, and neuropathic pain.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: January 17, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Vanessa Zambelli, Che-Hong Chen, Daria Mochly-Rosen
  • Use of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof in pharmaceutical compositions as a neuroretinal protector
    Patent number: 9545409
    Abstract: The use of 1-adamantylethyloxy-3-morpholino-2-propanol, or pharmaceutically acceptable salts thereof, in a concentration range of from 3 to 100 mg/ml in pharmaceutical compositions for parenteral administration in the treatment of degenerative neuroretinal diseases of various geneses.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: January 17, 2017
    Inventor: Gleb Vladimirovich Zagorii
  • Selegiline transdermal system
    Patent number: 9539201
    Abstract: Embodiments of the invention relate generally to the field of transdermal delivery and more specifically to transdermal patches containing selegiline base for the treatment of depression, Parkinson's disease, and other nervous system conditions.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: January 10, 2017
    Assignee: KAT Transdermals LLC
    Inventors: Kirti H. Valia, Thomas Mark Rossi, Agis Kydonieus
  • Prevention and treatment of thromboembolic disorders
    Patent number: 9539218
    Abstract: The present invention relates to the field of blood coagulation, more specifically it relates to a method of treating a thromboembolic disorder by administering once daily a direct factor Xa inhibitor in oral dosage form to a patient in need thereof, wherein the factor Xa inhibitor has a plasma concentration half life indicative of a bid or tid administration interval, e.g. of 10 hours or less.
    Type: Grant
    Filed: January 19, 2006
    Date of Patent: January 10, 2017
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Frank Misselwitz, Dagmar Kubitza, Son-Mi Park, Klaus Wehling
  • Bromfenac bioavailability
    Patent number: 9517220
    Abstract: Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY™ formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: December 13, 2016
    Assignee: Bausch & Lomb Pharma Holdings Corp.
    Inventors: Angel Padilla, George Baklayan
  • Cosmetic compositions and methods providing enhanced penetration of skin care actives
    Patent number: 9511144
    Abstract: A cosmetic composition suitable for topical application is provided. In some examples, the cosmetic composition can include glycerin, hexyldecanol, a vitamin B compound, and one or more materials selected from the group consisting of 1,2-pentanediol, 1,4-pentanediol, 2,4-pentanediol, 1,5-pentanediol, 1,2-butanediol, 1,3-butanediol, 1,4-butanediol, 2,3-butanediol, 1,2-hexanediol, 1,5-hexanediol, 1,6-hexanediol, 2,5-hexanediol, hexylene glycol, and combinations thereof.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 6, 2016
    Assignee: The Proctor & Gamble Company
    Inventors: Stevan David Jones, Kunal Virendra Gujraty, Naohisa Yoshimi, Monalisha Paul, James Terence Wescott
  • Methods for reducing body fat
    Patent number: 9504695
    Abstract: Provided are methods, compositions, systems, and kits for treating metabolic syndrome or a disorder associated with metabolic syndrome, e.g., obesity, dyslipidemia, and/or a diabetic condition, comprising administering systemically to a subject one or more compounds of the Formula (I) and/or (II): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein , L, R1, R2, Z, X, A and B are defined herein.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: November 29, 2016
    Assignee: Topokine Therapeutics, Inc.
    Inventor: Murat V. Kalayoglu
  • Antimicrobial composition
    Patent number: 9504248
    Abstract: The present invention relates to an antimicrobial composition and a method for disinfection involving the antimicrobial composition. It particularly relates to an antimicrobial composition for personal cleaning, oral care or hard surface cleaning applications. It was found that compositions comprising one or more monosubstituted phenols, terpineol and a carrier provide synergistic antimicrobial action. In a preferred aspect the composition also comprises 1 to 80%-wt of one or more surfactants.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: November 29, 2016
    Assignee: Rohm and Haas Company
    Inventors: Robert J. Cornmell, Megan A. Diehl, Stephen Golding, John R. Harp, Ian P. Stott, Katherine M. Thompson, Carol L. Truslow
  • 2-pyrones
    Patent number: 9499508
    Abstract: The present invention relates to the use of compounds of the formula (I) for the care, preservation or improvement of the general condition or appearance of the skin or hair, and to preparations comprising compounds of the formula (I).
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: November 22, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Christophe Carola, Tatjana Mueller
  • Pharmaceutical composition comprising omega-(arylsulfonyl)alkylnitrile
    Patent number: 9481644
    Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a ?-(arylsulfonyl)alkylnitrile compound, or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering an ?-(arylsulfonyl)alkylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: November 1, 2016
    Assignee: OLATEC THERAPEUTICS LLC
    Inventors: Joseph St. Laurent, Gerald S. Jones, David M. Bresse